Novavax (NVAX) Capital Leases: 2012-2025
Historic Capital Leases for Novavax (NVAX) over the last 4 years, with Sep 2025 value amounting to $2.3 million.
- Novavax's Capital Leases fell 95.83% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 95.83%. This contributed to the annual value of $53.7 million for FY2024, which is 3.93% down from last year.
- As of Q3 2025, Novavax's Capital Leases stood at $2.3 million, which was down 95.67% from $52.4 million recorded in Q2 2025.
- Over the past 5 years, Novavax's Capital Leases peaked at $55.9 million during Q4 2023, and registered a low of $2.3 million during Q3 2025.
- Over the past 3 years, Novavax's median Capital Leases value was $53.2 million (recorded in 2023), while the average stood at $45.1 million.
- Per our database at Business Quant, Novavax's Capital Leases soared by 79.02% in 2023 and then tumbled by 95.83% in 2025.
- Quarterly analysis of 5 years shows Novavax's Capital Leases stood at $9.2 million in 2021, then reached $31.2 million in 2022, then spiked by 79.02% to $55.9 million in 2023, then decreased by 3.93% to $53.7 million in 2024, then slumped by 95.83% to $2.3 million in 2025.
- Its Capital Leases was $2.3 million in Q3 2025, compared to $52.4 million in Q2 2025 and $53.1 million in Q1 2025.